We’re making history, one milestone at a time
Follow our progress as we work toward our vision of improving outcomes for people with cancer.
October 14, 2021
Tizona Initiates Phase 1b Expansion Study of TTX-080 in Advanced Refractory or Resistant Malignancies
September 15, 2020
Tizona Appoints Christine O’Brien as Chief Executive Officer
July 21, 2020
Gilead Sciences Secures Exclusive Option to Acquire Tizona Therapeutics for $300 Million.
June 25, 2020
Tizona Initiates Clinical Development of TTX-080 in Advanced Cancers
February 19, 2020
Tizona to Present at The Cowen and Company 40th Annual Healthcare Conference